Abstract:The remarkable increase of neurodegenerative diseases has become a serious public health problem. Considering the lack of effective treatments to address these diseases and the difficulties in accessing the brain due to the blood–brain barrier, to attain a successful strategy to improve drug delivery to the brain, the administration route becomes a point of interest. In this emergence, the present investigation is designed to develop the chitosan-coated peptide-loaded nano-lipid carrier (CSPepNLC) and characterized by various physico-chemical methods such as laser light scattering for particle size and size distribution, zeta-potential, scanning electron microscope (SEM), X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), loading, and association efficiency and peptide release rate. The stability of CSPepNLC is screened in plasma, erythrocytes, and genotoxicity in pUC18. In addition, we examined the hatching rate, heart rate, survival rate, mortality rate, deformities, and apoptosis and embryo toxicity in Danio rerio model. Initially, NLC-S1, S2, S3, and S4 and nano-lipid carriers are formulated, and NLC-S4 is selected for the CSPepNLC formulation. CSPepNLC exhibited a particle size of 113.33 nm with PDI 0.301 and zeta potential + 28.18 mV. The association, loading efficiency, and release rate of CSPepNLC were observed to be 94.41 ± 0.943%, 11.54 ± 0.572%, and 57% at 30 h. Formulated CSPepNLC was spherical in shape whose size ranges 110–120 nm. Finally, FTIR results confirmed the formation and stability of CSPepNLC. The CSPepNLC exhibited 85% stability at 150 min when incubated with plasma; miniscule hemolysis and absence of hemagglutination are noticed after incubation with erythrocytes. The CSPepNLC revealed the absence of genotoxicity in the pUC18 plasmid DNA nicking assay. The embryo toxicity of CSPepNLC in zebrafish is observed in a time- and dose-dependent manner. Our proposed results concluded that CSPepNLC is observed to be nontoxic at lower concentrations (12.5–100 μg/ml). In specifically, 200 μg/ml of CSPepNLC causes slight zebrafish embryo deformities while screening. Finally, although these results seem promising, further modifications in the CSPepNLC formulation are defensible to enhance the percentage of particles reaching the brain after their administration. This desirable drug carrier system demonstrates advantages such as good biocompatibility, low toxicity, drug release modulation, and the possibility of established mass production. The emergence of nanomaterial research is an important and new prospect to develop unique techniques widely used against several pharmaceutical applications. In this study, the obtained results proved that biogenic nanomaterial are great promising biological activity for a developing sustainable ecosystem.

Nose to brain delivery of escitalopram-loaded nano-structured lipid carriers thermosensitive gel: Formulation, physiochemical, pharmacokinetic and pharmacodynamics evaluation

Paroxetine Loaded Nanostructured Lipid Carriers Based In-situ Gel for Brain Delivery via Nasal Route for Enhanced Anti-Depressant Effect: In Vitro Prospect and In Vivo Efficacy

Levosulpiride-loaded nanostructured lipid carriers for brain delivery with antipsychotic and antidepressant effects

Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation

Brain targeting of cefepime loaded transfersomes based thermosensitive in situ gel via intranasal delivery: In vitro and in vivo studies

Quercetin-Loaded Nanostructured Lipid Carrier In Situ Gel for Brain Targeting Through Intranasal Route: Formulation, In Vivo Pharmacokinetic and Pharmacodynamic Studies

Manipulation of Lipid Nanocapsules as an Efficient Intranasal Platform for Brain Deposition of Clozapine as an Antipsychotic Drug

Nose to brain delivery of mirtazapine via lipid nanocapsules: Preparation, statistical optimization, radiolabeling, in vivo biodistribution and pharmacokinetic study

Design, preparation, and in vitro characterizations of chitosan-loaded nanostructured lipid carriers: a promising drug delivery system

Development, characterization and pharmacokinetic evaluation of selegiline HCl loaded cubosomal thermoreversible mucoadhesive gel for nose to brain delivery

Optimizing Intranasal Amisulpride Loaded Nanostructured Lipid Carriers: Formulation, Development, and Characterization Parameters

Intranasal delivery of doxepin: enhancing brain targeting efficiency utilizing nanostructured lipid carriers for a biopharmaceutics drug disposition classification system class-I drug

Qbd-Based Approach to Optimize Niosomal Gel of Levosulpiride for Transdermal Drug Delivery

Quality by Design Approach for the Development of Cariprazine Hydrochloride Loaded Lipid-Based Formulation for Brain Delivery via Intranasal Route

Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: Formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation

Intranasal Nanotransferosomal Gel for Quercetin Brain Targeting: I. Optimization, Characterization, Brain Localization, and Cytotoxic Studies

Development and Characterization of Eudragit Rl100 Nanoparticle Loaded Duloxetine Hydrochloride Gel for Transdermal Drug Delivery

Intranasal Nanotransferosomal Gel for Quercetin Brain Targeting: II. Antidepressant Effect in an Experimental Animal Model

Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: in vitro optimization and in vivo appraisal

Formulation, Development, and in-vitro Evaluation of Escitalopram Fast Dissolving Tablets

Brain Targeted Intranasal Zaleplon Nano-emulsion: In-Vitro Characterization and Assessment of Gamma Aminobutyric Acid Levels in Rabbits' Brain and Plasma at Low and High Doses